 | • レポートコード：GIR-107A11937 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、103ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥783,000 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、NSCLC用標的薬VEGFR2阻害剤のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。NSCLC用標的薬VEGFR2阻害剤の種類別市場規模（ラムシルマブ、その他）、用途別市場規模（NSCLC扁平上皮がん、NSCLC腺がん、NSCLC大細胞がん）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・NSCLC用標的薬VEGFR2阻害剤の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：ImClone Systems (Eli Lilly) ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：ラムシルマブ、その他 ・用途別分析2016年-2026年：NSCLC扁平上皮がん、NSCLC腺がん、NSCLC大細胞がん ・NSCLC用標的薬VEGFR2阻害剤の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・NSCLC用標的薬VEGFR2阻害剤のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・NSCLC用標的薬VEGFR2阻害剤のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・NSCLC用標的薬VEGFR2阻害剤の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・NSCLC用標的薬VEGFR2阻害剤の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Targeted Drug VEGFR2 Inhibitors for NSCLC market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Targeted Drug VEGFR2 Inhibitors for NSCLC size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Targeted Drug VEGFR2 Inhibitors for NSCLC market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Targeted Drug VEGFR2 Inhibitors for NSCLC market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Ramucirumab
Other
Market segment by Application, can be divided into
Squamous Cell Carcinoma of NSCLC
Adenocarcinoma of NSCLC
Large Cell Carcinoma of NSCLC
Market segment by players, this report covers
ImClone Systems (Eli Lilly)
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Targeted Drug VEGFR2 Inhibitors for NSCLC
1.2 Classification of Targeted Drug VEGFR2 Inhibitors for NSCLC by Type
1.2.1 Overview: Global Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue Market Share by Type in 2020
1.2.3 Ramucirumab
1.2.4 Other
1.3 Global Targeted Drug VEGFR2 Inhibitors for NSCLC Market by Application
1.3.1 Overview: Global Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Squamous Cell Carcinoma of NSCLC
1.3.3 Adenocarcinoma of NSCLC
1.3.4 Large Cell Carcinoma of NSCLC
1.4 Global Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size & Forecast
1.5 Global Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size and Forecast by Region
1.5.1 Global Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size by Region, (2016-2021)
1.5.3 North America Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size and Prospect (2016-2026)
1.5.4 Europe Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size and Prospect (2016-2026)
1.5.6 South America Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Targeted Drug VEGFR2 Inhibitors for NSCLC Market Drivers
1.6.2 Targeted Drug VEGFR2 Inhibitors for NSCLC Market Restraints
1.6.3 Targeted Drug VEGFR2 Inhibitors for NSCLC Trends Analysis
2 Company Profiles
2.1 ImClone Systems (Eli Lilly)
2.1.1 ImClone Systems (Eli Lilly) Details
2.1.2 ImClone Systems (Eli Lilly) Major Business
2.1.3 ImClone Systems (Eli Lilly) Targeted Drug VEGFR2 Inhibitors for NSCLC Product and Solutions
2.1.4 ImClone Systems (Eli Lilly) Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 ImClone Systems (Eli Lilly) Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Targeted Drug VEGFR2 Inhibitors for NSCLC Players Market Share
3.2.2 Top 10 Targeted Drug VEGFR2 Inhibitors for NSCLC Players Market Share
3.2.3 Market Competition Trend
3.3 Targeted Drug VEGFR2 Inhibitors for NSCLC Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue and Market Share by Type (2016-2021)
4.2 Global Targeted Drug VEGFR2 Inhibitors for NSCLC Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue Market Share by Application (2016-2021)
5.2 Targeted Drug VEGFR2 Inhibitors for NSCLC Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Type (2016-2026)
6.2 North America Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Application (2016-2026)
6.3 North America Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size by Country
6.3.1 North America Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Country (2016-2026)
6.3.2 United States Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
6.3.3 Canada Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
6.3.4 Mexico Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Type (2016-2026)
7.2 Europe Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Application (2016-2026)
7.3 Europe Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size by Country
7.3.1 Europe Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Country (2016-2026)
7.3.2 Germany Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
7.3.3 France Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
7.3.5 Russia Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
7.3.6 Italy Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Type (2016-2026)
8.2 Asia-Pacific Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Application (2016-2026)
8.3 Asia-Pacific Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size by Region
8.3.1 Asia-Pacific Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Region (2016-2026)
8.3.2 China Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
8.3.3 Japan Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
8.3.4 South Korea Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
8.3.5 India Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
8.3.7 Australia Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Type (2016-2026)
9.2 South America Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Application (2016-2026)
9.3 South America Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size by Country
9.3.1 South America Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Country (2016-2026)
9.3.2 Brazil Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
9.3.3 Argentina Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Type (2016-2026)
10.2 Middle East & Africa Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Application (2016-2026)
10.3 Middle East & Africa Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size by Country
10.3.1 Middle East & Africa Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Country (2016-2026)
10.3.2 Turkey Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
10.3.4 UAE Targeted Drug VEGFR2 Inhibitors for NSCLC Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue (USD Million) by Region (2016-2021)
Table 5. Global Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue Market Share by Region (2021-2026)
Table 6. ImClone Systems (Eli Lilly) Corporate Information, Head Office, and Major Competitors
Table 7. ImClone Systems (Eli Lilly) Major Business
Table 8. ImClone Systems (Eli Lilly) Targeted Drug VEGFR2 Inhibitors for NSCLC Product and Solutions
Table 9. ImClone Systems (Eli Lilly) Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Global Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue (USD Million) by Players (2019-2021)
Table 11. Global Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue Share by Players (2019-2021)
Table 12. Breakdown of Targeted Drug VEGFR2 Inhibitors for NSCLC by Company Type (Tier 1, Tier 2 and Tier 3)
Table 13. Targeted Drug VEGFR2 Inhibitors for NSCLC Players Head Office, Products and Services Provided
Table 14. Targeted Drug VEGFR2 Inhibitors for NSCLC Mergers & Acquisitions in the Past Five Years
Table 15. Targeted Drug VEGFR2 Inhibitors for NSCLC New Entrants and Expansion Plans
Table 16. Global Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue (USD Million) by Type (2016-2021)
Table 17. Global Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue Share by Type (2016-2021)
Table 18. Global Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue Forecast by Type (2021-2026)
Table 19. Global Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Application (2016-2021)
Table 20. Global Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue Forecast by Application (2021-2026)
Table 21. North America Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Type (2016-2021) & (USD Million)
Table 22. North America Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Type (2021-2026) & (USD Million)
Table 23. North America Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Application (2016-2021) & (USD Million)
Table 24. North America Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Application (2021-2026) & (USD Million)
Table 25. North America Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Country (2016-2021) & (USD Million)
Table 26. North America Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Country (2021-2026) & (USD Million)
Table 27. Europe Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Type (2016-2021) & (USD Million)
Table 28. Europe Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Type (2021-2026) & (USD Million)
Table 29. Europe Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Application (2016-2021) & (USD Million)
Table 30. Europe Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Application (2021-2026) & (USD Million)
Table 31. Europe Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Country (2016-2021) & (USD Million)
Table 32. Europe Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Country (2021-2026) & (USD Million)
Table 33. Asia-Pacific Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Type (2016-2021) & (USD Million)
Table 34. Asia-Pacific Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Type (2021-2026) & (USD Million)
Table 35. Asia-Pacific Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Application (2016-2021) & (USD Million)
Table 36. Asia-Pacific Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Application (2021-2026) & (USD Million)
Table 37. Asia-Pacific Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Region (2016-2021) & (USD Million)
Table 38. Asia-Pacific Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Region (2021-2026) & (USD Million)
Table 39. South America Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Type (2016-2021) & (USD Million)
Table 40. South America Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Type (2021-2026) & (USD Million)
Table 41. South America Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Application (2016-2021) & (USD Million)
Table 42. South America Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Application (2021-2026) & (USD Million)
Table 43. South America Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Country (2016-2021) & (USD Million)
Table 44. South America Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Country (2021-2026) & (USD Million)
Table 45. Middle East & Africa Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Type (2016-2021) & (USD Million)
Table 46. Middle East & Africa Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Type (2021-2026) & (USD Million)
Table 47. Middle East & Africa Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Application (2016-2021) & (USD Million)
Table 48. Middle East & Africa Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Application (2021-2026) & (USD Million)
Table 49. Middle East & Africa Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Country (2016-2021) & (USD Million)
Table 50. Middle East & Africa Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Targeted Drug VEGFR2 Inhibitors for NSCLC Picture
Figure 2. Global Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue Market Share by Type in 2020
Figure 3. Ramucirumab
Figure 4. Other
Figure 5. Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue Market Share by Application in 2020
Figure 6. Squamous Cell Carcinoma of NSCLC Picture
Figure 7. Adenocarcinoma of NSCLC Picture
Figure 8. Large Cell Carcinoma of NSCLC Picture
Figure 9. Global Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 10. Global Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue and Forecast (2016-2026) & (USD Million)
Figure 11. Global Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue Market Share by Region (2016-2026)
Figure 12. Global Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue Market Share by Region in 2020
Figure 13. North America Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2016-2026)
Figure 14. Europe Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Asia-Pacific Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. South America Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Middle East and Africa Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Targeted Drug VEGFR2 Inhibitors for NSCLC Market Drivers
Figure 19. Targeted Drug VEGFR2 Inhibitors for NSCLC Market Restraints
Figure 20. Targeted Drug VEGFR2 Inhibitors for NSCLC Market Trends
Figure 21. ImClone Systems (Eli Lilly) Recent Developments and Future Plans
Figure 22. Global Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue Share by Players in 2020
Figure 23. Targeted Drug VEGFR2 Inhibitors for NSCLC Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 24. Global Top 3 Players Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue Market Share in 2020
Figure 25. Global Top 10 Players Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue Market Share in 2020
Figure 26. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 27. Global Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue Share by Type in 2020
Figure 28. Global Targeted Drug VEGFR2 Inhibitors for NSCLC Market Share Forecast by Type (2021-2026)
Figure 29. Global Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue Share by Application in 2020
Figure 30. Global Targeted Drug VEGFR2 Inhibitors for NSCLC Market Share Forecast by Application (2021-2026)
Figure 31. North America Targeted Drug VEGFR2 Inhibitors for NSCLC Sales Market Share by Type (2016-2026)
Figure 32. North America Targeted Drug VEGFR2 Inhibitors for NSCLC Sales Market Share by Application (2016-2026)
Figure 33. North America Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue Market Share by Country (2016-2026)
Figure 34. United States Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 35. Canada Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 36. Mexico Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 37. Europe Targeted Drug VEGFR2 Inhibitors for NSCLC Sales Market Share by Type (2016-2026)
Figure 38. Europe Targeted Drug VEGFR2 Inhibitors for NSCLC Sales Market Share by Application (2016-2026)
Figure 39. Europe Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue Market Share by Country (2016-2026)
Figure 40. Germany Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 41. France Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 42. United Kingdom Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 43. Russia Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 44. Italy Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Asia-Pacific Targeted Drug VEGFR2 Inhibitors for NSCLC Sales Market Share by Type (2016-2026)
Figure 46. Asia-Pacific Targeted Drug VEGFR2 Inhibitors for NSCLC Sales Market Share by Application (2016-2026)
Figure 47. Asia-Pacific Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue Market Share by Region (2016-2026)
Figure 48. China Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Japan Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. South Korea Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. India Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Southeast Asia Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Australia Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. South America Targeted Drug VEGFR2 Inhibitors for NSCLC Sales Market Share by Type (2016-2026)
Figure 55. South America Targeted Drug VEGFR2 Inhibitors for NSCLC Sales Market Share by Application (2016-2026)
Figure 56. South America Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue Market Share by Country (2016-2026)
Figure 57. Brazil Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Argentina Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Middle East and Africa Targeted Drug VEGFR2 Inhibitors for NSCLC Sales Market Share by Type (2016-2026)
Figure 60. Middle East and Africa Targeted Drug VEGFR2 Inhibitors for NSCLC Sales Market Share by Application (2016-2026)
Figure 61. Middle East and Africa Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue Market Share by Country (2016-2026)
Figure 62. Turkey Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Saudi Arabia Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. UAE Targeted Drug VEGFR2 Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Methodology
Figure 66. Research Process and Data Source
世界のNSCLC用標的薬物MEK阻害剤市場 2021：企業別、地域別、種類・用途別 The Targeted Drug MEK Inhibitors for NSCLC market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization…- 世界のNSCLC用標的薬BRAF阻害剤市場 2021：企業別、地域別、種類・用途別 The Targeted Drug BRAF Inhibitors for NSCLC market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizatio…
- 世界のNSCLC用標的薬ALK阻害剤市場 2021：企業別、地域別、種類・用途別 The Targeted Drug ALK Inhibitors for NSCLC market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization…
- 世界のNSCLC用標的薬VEGF阻害剤市場 2021：企業別、地域別、種類・用途別 The Targeted Drug VEGF Inhibitors for NSCLC market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizatio…
- 世界の多発性骨髄腫用標的薬市場 2021：企業別、地域別、種類・用途別 The Targeted Drugs for Multiple Myeloma market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, t…